Member Info for Timster

Already posted these links but here we go again:

we have this information from the CEO so we wait on the understanding that this is being done following due process:

Q4: I think you answered this earlier, but the COVID-19 rapid antigen test, when will that be available?

A4: So, I think as everyone knows we’re in the process of technology transfer and manufacturing scale up which is being carried out by BBI Solutions, one of our manufacturing partners and Cytiva. That is very much a development process, developing large scale robust manufacturing processes and, as I’ve said a number of times, the key milestone that we need to get to is the pilot batch of test devices. At that time, when we have that pilot batch and we’ve gone through that development process, we’ll be able to get a much clearer timeline to product launch.

It’s essential that that manufacturing process development is done properly because it’s a significant de-risking step, rushing it and ended up with a process that isn’t robust is a mistake and it simply pushes the risks down the line to the clinical validation, which I’m not prepared to allow.

So, we expect to carry out the clinical validation in Q4, as I said, and as soon as we have that pilot batch, I will be able to give a much clearer timeline through that clinical validation, CE marking and product launch.

The recording of the latest presentation is well worth a listen:
https://avacta.com/interim-results-for-the-period-ended-30-june-2020-webinar-presentation/

40 mins in tech transfer is discussed

@Ophidian - 12-14 months, hope not!!

You could well be right as in the results conference call Alastair did say that tech transfer wasn't a "tick box paper exercise". So what he is talking about is not what in your experience tech transfer entails.

https://avacta.com/interim-results-for-the-period-ended-30-june-2020-webinar-presentation/

40 mins in

Q4, Global that's when Al said they would be starting validation

we have this information from the CEO so we wait on the understanding that this is being done following due process:

Q4: I think you answered this earlier, but the COVID-19 rapid antigen test, when will that be available?

A4: So, I think as everyone knows we’re in the process of technology transfer and manufacturing scale up which is being carried out by BBI Solutions, one of our manufacturing partners and Cytiva. That is very much a development process, developing large scale robust manufacturing processes and, as I’ve said a number of times, the key milestone that we need to get to is the pilot batch of test devices. At that time, when we have that pilot batch and we’ve gone through that development process, we’ll be able to get a much clearer timeline to product launch.

It’s essential that that manufacturing process development is done properly because it’s a significant de-risking step, rushing it and ended up with a process that isn’t robust is a mistake and it simply pushes the risks down the line to the clinical validation, which I’m not prepared to allow.

So, we expect to carry out the clinical validation in Q4, as I said, and as soon as we have that pilot batch, I will be able to give a much clearer timeline through that clinical validation, CE marking and product launch.

£20 I'll take some out to pay the milk man

@richob, guess you mean the link I added it says healgen and is swab based

@travel_light yes we do have detailed information:
https://avacta.com/alastair-smith-gives-more-detail-on-the-sars-cov-2-elisa-laboratory-test/

it is also using the same Affimer's as BAMS and LFT

I think the time to validate is just down to the amount of samples available interestingly if you look at the government pages then sample sizes on some of the tests isnt that large:
https://www.gov.uk/government/publications/covid-19-phe-laboratory-assessments-of-molecular-tests

and the existing LFT's only have 130 -1200 odd samples:
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results

and then there's the Conifer Management, LLC to maintain our USA links

https://post.parliament.uk/the-latest-in-covid-19-testing-developing-new-technologies/

Testing technologies of Government interest
The Government is supporting innovation for improved testing technologies, both laboratory-based and more recently for tests that can be carried out at scale and at the point-of-care. The Government is also exploring whether other samples can be used, such as saliva rather than nose and throat swabs. Several companies mentioned in a recent Government statement are working on this:

Avacta: a laboratory test using mass spectrometry on nose and throat swabs and on saliva samples. The company is also developing an antigen saliva test.
Chronomics: a laboratory PCR test that can be carried out on saliva samples.
MAP Science: a laboratory test using mass spectrometry on saliva samples.
Oxford Nanoimaging: is developing a portable technology that uses microscopy to detect whole virus in samples including saliva.

Avacta's Affimers have been proven to be highly specific and sensitive:
https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf
slide 22

Bruker note:
https://bit.ly/33TD91p

can't be true! Trump has had it and now he's super human, eats COVID krispies for breakfast....

From a tweet today are busy evaluating this test this week
https://www.lumiradx.com/us-en/what-we-do/diagnostics/test-technology/antigen-test

not a competitor to Avacta's LFT though

having read @Captainstanley comments it is slightly concerning that since Myles announced selling NCYT yesterday it dropped 18%. Does he really have that much influence? or is it just the inevitable pause in the big gains there?

lets get back to why we are all here! everyone's research and opinions are valuable and this is what a discussion board is for.

If you don't like what someone posts and can constructively and articulately argue against it then great, just ignore it and move on or filter. Every chat forum has uber rampers, rampers, neutrals, negateers, uber negateers and bonkers posters.

Avacta is a fantastic company with so much potential and MASSIVE transformational projects in flight. With regards to COVID they have the full backing of the government too.

Hope we get some soon, give us something new to talk about rather than all this silly ******.

He knows as much as we all know read the last presentation, the major upcoming inflection points are listed in there.

https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf

thanks, I gathered that, but that's what the launch is for the Bruker toolkit tomorrow.

it says, their GxP reediness kit (or am I missing something)

@Yorkshirepragma

from latest presentation:
UK strip manufacturing capacity needs to be scaled rapidly to address the anticipated
volume requirements and additional capacity is being put in place overseas.
• Kit assembly is a challenge and partners in the UK have been identified and additional
resources overseas are being put in place.
• Detailed discussions with regulatory authorities, governments and healthcare providers
are ongoing but are strictly confidential.

Rk and Myles